Skip to content

Last week in biopharma partnering: May 29 – June 4, 2022

By admin June 6, 2022

Each week (well almost, some weeks are quite uneventful), we compile and curate hot-off-the-press news and updates on the happenings in the world of pharma and life sciences partnering.

Be sure to follow us and keep up-to-date on all things partnering to inform your decisions and strategies.

Xyphos Biosciences, Inc., (a wholly owned subsidiary of Astellas, “Xyphos”) and GO Therapeutics, Inc. announced a strategic research collaboration and license agreement to develop novel Immuno-Oncology therapeutics – see press release.

Repare Therapeutics Inc. announced a worldwide license and collaboration agreement with Roche for the development and commercialization of camonsertib (RP-3500), a small molecule inhibitor of ATR (Ataxia-Telangiectasia and Rad3-related protein kinase) for the treatment of tumors with specific synthetic-lethal genomic alterations including those in the ATM gene – see full article.

Pharma Intelligence, a leading provider of specialist intelligence, data, and software for clinical trials, drug development, and regulatory compliance, announces that Warburg Pincus, a global growth investor, has completed its acquisition of the business from Informa PLC – see press release.

Olink Holding AB announced that Pharma Foods International in Japan has initiated a partnership to use Olink technology to accelerate protein analysis services targeting Japanese customers – see full article.

Foghorn Therapeutics Inc. , a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, announced management’s participation in upcoming investor conferencessee press release.